Log in
Enquire now
‌

US Patent 12091397 Dihydroquinolinones for medical treatment

OverviewStructured DataIssuesContributors
Is a
Patent
Patent
0
Date Filed
August 1, 2022
0
Date of Patent
September 17, 2024
0
Patent Applicant
C4 Therapeutics
C4 Therapeutics
0
Patent Application Number
17878753
0
Patent Citations
‌
US Patent 9249161 Bromodomain inhibitors and uses thereof
0
‌
US Patent 10646575 Heterocyclic degronimers for target protein degradation
0
‌
US Patent 10660968 Spirocyclic degronimers for target protein degradation
0
‌
US Patent 10849982 C3-carbon linked glutarimide degronimers for target protein degradation
0
‌
US Patent 10905768 Heterocyclic degronimers for target protein degradation
0
‌
US Patent 11185592 Spirocyclic degronimers for target protein degradation
0
‌
US Patent 11254672 Dihydrobenzimidazolones for medical treatment
0
‌
US Patent 11401256 Dihydroquinolinones for medical treatment
0
‌
US Patent 11459335 N/O-linked Degrons and Degronimers for protein degradation
0
‌
US Patent 11407732 Tricyclic degraders of Ikaros and Aiolos
0
•••
Patent Inventor Names
Annick Goergler
0
Eric Andre Kusznir
0
Fabian Dey
0
Moreno Attilio Wichert
0
Roger Norcross
0
Adrian Britschgi
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
12091397
0
Patent Primary Examiner
‌
Medhanit W Bahta
0

Find more entities like US Patent 12091397 Dihydroquinolinones for medical treatment

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.